Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label Randomized Phase 1 Study to Investigate the Pharmacokinetics and Pharmacodynamics of Subcutaneous and Intravenous Administrations of Golimumab to Subjects With Rheumatoid Arthritis
Brief Summary: This is a Phase 1, pharmacokinetic and pharmacodynamic study of intravenous and subcutaneous administered golimumab in patients with rheumatoid arthritis.


Options:
A: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
B: Arm Label: Abatacept + Methotrexate (Double-blind period); Type: ACTIVE_COMPARATOR; Interventions: Drug: Abatacept | Arm Label: Placebo + Methotrexate (Double-blind period); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept + Methotrexate (Double-blind period) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo + Methotrexate (Double-blind period)
C: Arm Label: Placebo followed by Certolizumab Pegol (CZP); Type: OTHER; Interventions: Other: Placebo, Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Arm Label: Certolizumab Pegol (CZP); Type: EXPERIMENTAL; Interventions: Biological: Certolizumab Pegol (CZP) 200 mg, Biological: Certolizumab Pegol (CZP) 400 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 200 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP) | Intervention Type: BIOLOGICAL; Name: Certolizumab Pegol (CZP) 400 mg; Assigned to Arm(s): Certolizumab Pegol (CZP), Placebo followed by Certolizumab Pegol (CZP)
D: Arm Label: Group 1: Placebo + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Placebo injections, Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 2: Golimumab 100 mg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo capsules, Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 3: Golimumab 50 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Arm Label: Group 4: Golimumab 100 mg + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: Methotrexate capsules, Biological: Golimumab 50 mg injections, Biological: Golimumab 100 mg injections | Intervention Type: DRUG; Name: Placebo injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate | Intervention Type: DRUG; Name: Placebo capsules; Assigned to Arm(s): Group 2: Golimumab 100 mg + Placebo | Intervention Type: DRUG; Name: Methotrexate capsules; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: BIOLOGICAL; Name: Golimumab 50 mg injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate | Intervention Type: BIOLOGICAL; Name: Golimumab 100 mg injections; Assigned to Arm(s): Group 1: Placebo + Methotrexate, Group 2: Golimumab 100 mg + Placebo, Group 3: Golimumab 50 mg + Methotrexate, Group 4: Golimumab 100 mg + Methotrexate

Answer: A